Literature DB >> 14722240

Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro.

Eric Deprez1, Sophie Barbe, Macieij Kolaski, Hervé Leh, Fatima Zouhiri, Christian Auclair, Jean-Claude Brochon, Marc Le Bret, Jean-François Mouscadet.   

Abstract

Styrylquinoline derivatives (SQ) efficiently inhibit the 3'-processing activity of integrase (IN) with IC50 values of between 0.5 and 5 microM. We studied the mechanism of action of these compounds in vitro. First, we used steady-state fluorescence anisotropy to assay the effects of the SQ derivatives on the formation of IN-viral DNA complexes independently of the catalytic process. The IC50 values obtained in activity and DNA-binding tests were similar, suggesting that the inhibition of 3'-processing can be fully explained by the prevention of IN-DNA recognition. SQ compounds act in a competitive manner, with Ki values of between 400 and 900 nM. In contrast, SQs did not inhibit 3'-processing when IN-DNA complexes were preassembled. Computational docking followed or not by molecular dynamics using the catalytic core of HIV-1 IN suggested a competitive inhibition mechanism, which is consistent with our previous data obtained with the corresponding Rous sarcoma virus domain. Second, we used preassembled IN-preprocessed DNA complexes to assay the potency of SQs against the strand transfer reaction, independently of 3'-processing. Inhibition occurred even if the efficiency was decreased by about 5- to 10-fold. Our results suggest that two inhibitor-binding modes exist: the first one prevents the binding of the viral DNA and then the two subsequent reactions (i.e., 3'-processing and strand transfer), whereas the second one prevents the binding of target DNA, thus inhibiting strand transfer. SQ derivatives have a higher affinity for the first site, in contrast to that observed for the diketo acids, which preferentially bind to the second one.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722240     DOI: 10.1124/mol.65.1.85

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  20 in total

1.  Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.

Authors:  Supachai Sakkhachornphop; Carlos F Barbas; Rassamee Keawvichit; Kanlaya Wongworapat; Chatchai Tayapiwatana
Journal:  Hum Gene Ther       Date:  2012-05-08       Impact factor: 5.695

2.  Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Authors:  S P Korolev; Yu Yu Agapkina; M B Gottikh
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

3.  Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium.

Authors:  Zvi Hayouka; Joseph Rosenbluh; Aviad Levin; Shoshana Loya; Mario Lebendiker; Dmitry Veprintsev; Moshe Kotler; Amnon Hizi; Abraham Loyter; Assaf Friedler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-08       Impact factor: 11.205

4.  Multiple Escherichia coli RecQ helicase monomers cooperate to unwind long DNA substrates: a fluorescence cross-correlation spectroscopy study.

Authors:  Na Li; Etienne Henry; Elvire Guiot; Pascal Rigolet; Jean-Claude Brochon; Xu-Guang Xi; Eric Deprez
Journal:  J Biol Chem       Date:  2010-01-04       Impact factor: 5.157

5.  Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.

Authors:  Ira B Dicker; Brian Terry; Zeyu Lin; Zhufang Li; Sagarika Bollini; Himadri K Samanta; Volodymyr Gali; Michael A Walker; Mark R Krystal
Journal:  J Biol Chem       Date:  2008-06-24       Impact factor: 5.157

6.  Designed zinc finger protein interacting with the HIV-1 integrase recognition sequence at 2-LTR-circle junctions.

Authors:  Supachai Sakkhachornphop; Supat Jiranusornkul; Kanchanok Kodchakorn; Sawitree Nangola; Thira Sirisanthana; Chatchai Tayapiwatana
Journal:  Protein Sci       Date:  2009-11       Impact factor: 6.725

7.  Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones.

Authors:  Joël Didierjean; Catherine Isel; Flore Querré; Jean-François Mouscadet; Anne-Marie Aubertin; Jean-Yves Valnot; Serge R Piettre; Roland Marquet
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

8.  Prospective strategies for targeting HIV-1 integrase function.

Authors:  Yang Luo; Mark A Muesing
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

9.  A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain.

Authors:  Kevin Carayon; Hervé Leh; Etienne Henry; Françoise Simon; Jean-François Mouscadet; Eric Deprez
Journal:  Nucleic Acids Res       Date:  2010-02-17       Impact factor: 16.971

Review 10.  Integrase and integration: biochemical activities of HIV-1 integrase.

Authors:  Olivier Delelis; Kevin Carayon; Ali Saïb; Eric Deprez; Jean-François Mouscadet
Journal:  Retrovirology       Date:  2008-12-17       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.